NYSEMKT: OCXONCOCYTE CORP Stock
$1.02+0.00 (+0%)
Updated Jun 24, 2022
OCX Price
$1.02
Fair Value Price
N/A
Market Cap
$120.88M
52 Week Low
$0.84
52 Week High
$6.25
P/E
-1.31x
P/B
2.12x
P/S
17.12x
PEG
N/A
Dividend Yield
N/A
Revenue
$8.03M
Earnings
-$70.47M
Gross Margin
-5.3%
Operating Margin
-896.91%
Profit Margin
-877.9%
Debt to Equity
1.57
Operating Cash Flow
-$39M
Beta
1.14
Next Earnings
Aug 8, 2022
Ex-Dividend
N/A
Next Dividend
N/A
OCX Overview
Zen Score
–
Industry Average (30)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how OCX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OCX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
OCX is good value based on its book value relative to its share price (2.12x), compared to the US Biotechnology industry average (4.43x)
P/B vs Industry Valuation
OCX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more OCX due diligence checks available for Premium users.
OCX News
Valuation
OCX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.31x
Industry
-2.58x
Market
20.48x
OCX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.12x
Industry
4.43x
OCX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
OCX's financial health
Profit margin
Revenue
$1.4M
Net Income
-$10.3M
Profit Margin
-722.7%
OCX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
OCX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$146.3M
Liabilities
$89.3M
Debt to equity
1.57
OCX's short-term assets ($24.62M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OCX's long-term liabilities ($75.35M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OCX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
OCX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$13.3M
Investing
-$1.6M
Financing
-$355.0k
OCX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
OCX vs Biotech Stocks
ONCOCYTE Stock FAQ
©2022 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.